Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Geovax Labs

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies and vaccines against cancers and infectious diseases using a novel vector vaccine platform. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus (HIV), as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GeoVax Labs advances cancer therapies and COVID-19 vaccine development

GeoVax Labs showcased advancements in cancer therapies and COVID-19 vaccine development, underlining a commitment to innovation and global healthcare improvement.
While facing financial challenges due to increased R&D expenses and net loss, GeoVax's strategic strengths in vaccine development and clinical trials offer promising opportunities for growth.
The completion of the Gedeptin trial, ongoing Phase II trials for CM04S1, and plans for future vaccine developments position GeoVax for impactful contributions to healthcare.

GeoVax Labs reports Q2 loss, progresses in key trials

GeoVax's Q2 performance reflects ongoing investment in R&D and progress in key clinical trials.
The company's strengths lie in securing funding, commitment to innovation, and vaccine differentiation.
Challenges include recruitment issues, funding needs, and uncertainties in the pipeline.
Opportunities exist in fundraising, vaccine development, expanding indications, and optimizing clinical trials.

GeoVax Labs reports Q3 progress with vaccine trials and financial challenges

GeoVax Labs' Q3 performance reflects a mix of achievements and challenges, with a focus on advancing vaccine candidates and managing financials. The company's strengths in innovation and clinical trial strategies position it well for future growth opportunities through partnerships and regulatory advancements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript

Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m.

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024 in New York, NY. Senior GeoVax management will also host one-on-one meetings with registered attendees.

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, will present at two upcoming investor events:

GeoVax to Participate in Upcoming Investor Conferences in September

ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company's common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules.

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

After reaching an important support level, GeoVax Labs Inc. (GOVX) could be a good stock pick from a technical perspective. GOVX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Should You Buy GeoVax Labs Inc. (GOVX) After Golden Cross?

GeoVax Labs NASDAQ: GOVX is currently a micro-cap biotech stock that multiple Wall Street analysts see massive potential appreciation in. Working on a treatment for a disease that the World Health Organization (WHO) just declared a “public health emergency," investors should be informed about the company.

GeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?

GeoVax Labs Inc.'s stock GOVX, +1.27% tumbled 20% in premarket trade Tuesday, after the clinical-stage biotech said it's entered an agreement with an institutional investor for the purchase and sale of 1.7 million shares priced at $5 each in a registered direct offering. The stock closed Monday up 1.7% at $7.15, after a rollercoaster session that saw it soar more than 40% at its peak, on excitement about its work to develop an mpox vaccine.

GeoVax's stock slides 20% after company raises $8.5 million in stock sale

ATLANTA, GA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1,700,000 shares of the Company's common stock (or common stock equivalents) at a price of $5.00 per share in a registered direct offering priced above-the-market under Nasdaq rules.

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

Citizens

Cadrenal Therapeutics Inc

Elutia Inc

Euda Health Holdings Ltd

Cytomed Therapeutics Ltd

Gossamer Bio Inc

Immuron

Intelligent Bio Solutions Inc

iQSTEL Inc.

Prospector LeddarTech Almalco

Nature's Miracle California Inc

Pure Cycle

Peraso

SunCar Technology Group Inc

22nd Century Group

MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Applied DNA Sciences

Emergent BioSolutions

Virax Biolabs Group Ltd

Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.

WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch

GeoVax Labs Inc.'s stock soared 54% early Monday to lead a fresh rally among companies developing treatments for mpox, after rival Siga Technologies Inc. said a trial of its antiviral failed to meet its main goal.

GeoVax's stock soars 54% to lead rally in companies developing mpox treatments

Company to Discuss Recent Mpox Developments as Well as Milestones Related to the BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine

GeoVax to Present at the Emerging Growth Conference on August 21, 2024

SIGA Technologies

The World Health Organisation on Wednesday declared the upsurge of monkeypox virus or ‘Mpox' in Africa a public health emergency of international concern (PHEIC), stating it had the potential to spread across countries in Africa and possibly outside the continent.

Mpox outbreak: 5 stocks to watch out for as the emergency unfolds

GeoVax Labs, Inc. (NASDAQ:GOVX ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Max Gadicke - Investor Relations David Dodd - Chairman & Chief Executive Officer Mark Reynolds - Chief Financial Officer Kelly McKee - Chief Medical Officer Conference Call Participants Robert LeBoyer - Noble Capital Markets Jason Kolbert - EF Hutton Jeff Kraws - Crystal Research Operator Good afternoon and welcome everyone to the GeoVax Second Quarter 2024 Corporate Update Call. My name is Alex and I will facilitate today's call.

GeoVax Labs, Inc. (GOVX) Q2 2024 Earnings Call Transcript

Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI).

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor

Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

Geovax Labs (NASDAQ: GOVX ) stock is jumping on Tuesday as investors in GOVX prepare for a catalyst on July 18. That's when Geovax Labs will hold a presentation at the Emerging Growth Conference.

GeoVax (GOVX) Stock Pops Ahead of July 18 Catalyst

Biotechnology specialist GeoVax (NASDAQ: GOVX ) — which focuses on developing immunotherapies and vaccines against cancers and infectious diseases — just announced a partnership with global clinical research organization Allucent. The main purpose behind the agreement is to conduct a Phase 2b clinical trial of GeoVax's next-generation Covid-19 vaccine.

Why Is GeoVax (GOVX) Stock Up 110% Today?

GeoVax Labs, Inc. (NASDAQ:GOVX ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Max Gadicke - Investor Relations, Stern IR David Dodd - Chairman & Chief Executive Officer Mark Reynolds - Chief Financial Officer Kelly McKee - Chief Medical Officer John Sharkey - Vice President, Business Development Conference Call Participants Robert LeBoyer - Noble Capital Markets Operator Good afternoon, and welcome everyone to the GeoVax First Quarter 2024 Corporate Update Call. My name is Mark, and I will facilitate today's call.

GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript

Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, presented data on GEO-CM04S1, the Company's next-generation Covid-19 vaccine candidate, during the 24th Annual World Vaccine Congress in Washington, DC. During his presentation, titled “Vaccine Induction of Broadly-Specific Antibody and T Cell Responses to Combat SARS-CoV-2 Variation”, Dr. Newman described GeoVax's development program for GEO-CM04S1.

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chief Scientific Officer, Mark Newman, PhD, will present data on GEO-CM04S1, the Company's next-generation Covid-19 vaccine candidate, during the upcoming 24th Annual World Vaccine Congress taking place in Washington, DC on April 1-4, 2024.

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 36th Annual Roth Conference, taking place in Dana Point, CA on March 17-19, 2024.

News for Geovax Labs Stock (GOVX)